AK104 with chemo and targeted therapy for advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have metastatic colorectal cancer that cannot be removed by surgery.
- Your tumor must be MSI-L or MSS (not MSI-H) and not have a BRAF mutation.
- You can only have had one prior treatment for metastatic disease, based on oxaliplatin (FOLFOX or CAPOX).
- You need to have at least one tumor that can be measured on scans.
- Your overall health must be good, with normal blood counts, kidney and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
This trial tests a new combination of drugs (Ivosidenib/AK112, CapeOX chemotherapy, and radiation) for people with advanced colorectal cancer that has spread and cannot be removed with surgery. It is for those whose tumors are MSS (microsatellite stable) type and who have not received recent chemotherapy.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
This Phase 2 study tests whether giving radiation and chemotherapy along with a drug called AK104 before surgery can better treat stage II or III rectal cancer. The goal is to improve cancer control while keeping side effects acceptable before your tumor is removed.
Hear when a new Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.